Is Kodak having a "Kodak moment?" 2 watchlist stocks.

Kodak's latest-quarter revenue rose 18% year over year to $311 million, led by 10% print growth and 40% growth in its Advanced Materials and Chemicals segment; gross margin expanded 700bps to 26% and operational EBITDA increased to $36 million from $9 million. The analysis sees potential valuation support from a roughly $144 million annualized EBITDA run rate versus a $731 million enterprise value, but maintains a Neutral rating because quarterly free cash flow was slightly negative. NeurAxis revenue more than doubled to $1.9 million, but its operating loss widened to $2.1 million and its approximately 12x TTM EV/sales valuation, dilution risk, and lack of operating leverage support a Neutral stance.

Analysis

KODK's apparent earnings leverage is not yet equivalent to cash-generation leverage. A print upcycle can improve fixed-cost absorption quickly, but consumables and plate demand are cyclical and the recent margin step-up must persist through at least two additional quarters before the market can underwrite a normalized multiple. The key valuation debate is therefore not the implied EBITDA multiple, but whether maintenance capex, working-capital needs, pension/legacy obligations and restructuring cash costs allow meaningful conversion into free cash flow.

The advanced-materials optionality has asymmetric appeal but should be valued near zero until Kodak discloses contracted volumes, customer concentration, required capex and segment-level contribution margins. EV-battery and pharma-reagent markets are qualification-intensive, with long lead times and entrenched suppliers; an announced pilot or partnership can create a sharp retail-driven move without changing near-term earnings. Conversely, credible multiyear offtake agreements could justify separating AMC from the mature print business and drive multiple expansion over 6-18 months.

NRXS is a different setup: reimbursement wins and higher realized pricing can support revenue growth, but its small revenue base means commercial spend and dilution are likely to outrun operating leverage over the next 1-3 quarters. At a premium revenue multiple, any deceleration in procedure adoption, payer coverage, or selling-price realization would be more consequential than another headline growth quarter. There is no read-through to AMZN, GOOG or NVDA; their inclusion is promotional-content noise rather than an investable linkage.

Key Decisions for Investors

• KODK: remain on watch rather than initiate. Upgrade to a tactical long only after two consecutive quarters of positive free cash flow and stable/improving gross margin; target a 6-12 month rerating if AMC backlog or offtake contracts become disclosed. Falsifier: renewed cash burn despite reported EBITDA growth or print revenue reverting to decline.
• For existing KODK exposure, treat AMC announcements without disclosed economics as liquidity events to trim rather than add. A credible entry requires evidence that AMC growth is not being funded by working-capital expansion or incremental leverage.
• NRXS: avoid long exposure at the current revenue multiple until quarterly revenue is large enough to demonstrate sales-and-marketing efficiency and the cash runway is clearly funded without a material ATM increase. Watch payer coverage expansion and revenue growth versus operating-loss growth over the next two quarters.
• Relative-value expression for investors seeking healthcare exposure: favor profitable medtech reimbursement beneficiaries over NRXS rather than shorting a thinly traded micro-cap; the principal risk in NRXS is financing/dilution, but borrow availability and squeeze risk make a direct short unattractive.